Please login to the form below

Not currently logged in

Former Novartis president joins Qu Biologics

Robert Pelzer is appointed board member at immunotherapy specialists

Qu Biologics Robert Pelzer

Qu Biologics has appointed former president of Novartis' US operations Robert Pelzer to its board of directors.

Pelzer was appointed president of Novartis Corporation in 2008, holding responsibility for Novartis' operations in North America.

He was previously global general counsel and head of legal services for Novartis at a corporate level.

Before joining Novartis in 2002, he spent several years at DuPont Pharmaceuticals, serving as general counsel and senior VP.

His senior industry experience will support Qu Biologics' plans to advance the development of its investigational immunotherapies for treatments such as Crohn's disease.

“Bob Pelzer's wealth of leadership experience with Novartis and DuPont will be invaluable to Qu Biologics during this important stage of our growth and development,” said CEO of Qu Biologics Dr Hal Gunn, who also noted that Pelzer will help develop relationships with potential pharma partners.

18th June 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....
The Periodic Table of Healthcare Communications
The definitive framework for building healthcare communication strategies and plans. Covering Brand Planning, Customer Experience and Multi-channel Marketing....